Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Huys

Showing results (71-80 of 206) with videos related to

Pageof 21
Sort By:
Frontiers in Pharmacology|December 28, 2020
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative TherapiesSissel Michelsen, Salma Nachi, Walter Van Dyck, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|May 17, 2015
Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013Kim Pauwels, Isabelle Huys, Katelijne De Nys, et al.
Regulatory Toxicology and Pharmacology : RTP|January 17, 2015
Causes of drug shortages in the legal pharmaceutical frameworkElfi De Weerdt, Steven Simoens, Luc Hombroeckx, et al.
NPJ Digital Medicine|August 16, 2024
EU-US data transfers: an enduring challenge for health research collaborationsTeodora Lalova-Spinks, Peggy Valcke, John P A Ioannidis, et al.
Frontiers in Medicine|April 9, 2020
Patient Centricity in Patient Preference Studies: The Patient PerspectiveEline van Overbeeke, Inès Vanbinst, Aura Cecilia Jimenez-Moreno, et al.
Journal of Market Access & Health Policy|April 15, 2020
Economic evaluation of biosimilars for reimbursement purposes - what, when, how?Evelien Moorkens, Hannah Broux, Isabelle Huys, et al.
Targeted Oncology|November 19, 2013
Market access of cancer drugs in European countries: improving resource allocationKim Pauwels, Isabelle Huys, Minne Casteels, et al.
Expert Opinion on Biological Therapy|May 26, 2025
Evolving global regulatory landscape for approval of biosimilars: current challenges and opportunities for convergenceElif Car, Liese Barbier, Isabelle Huys, et al.
Health Research Policy and Systems|July 6, 2023
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysisYannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.
Plos One|March 29, 2017
Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory studyElfi De Weerdt, Thomas De Rijdt, Steven Simoens, et al.
Pageof 21

Showing results (71-80 of 206) with videos related to

Sort By:
Pageof 21
Frontiers in Pharmacology|December 28, 2020
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative TherapiesSissel Michelsen, Salma Nachi, Walter Van Dyck, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|May 17, 2015
Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013Kim Pauwels, Isabelle Huys, Katelijne De Nys, et al.
Regulatory Toxicology and Pharmacology : RTP|January 17, 2015
Causes of drug shortages in the legal pharmaceutical frameworkElfi De Weerdt, Steven Simoens, Luc Hombroeckx, et al.
NPJ Digital Medicine|August 16, 2024
EU-US data transfers: an enduring challenge for health research collaborationsTeodora Lalova-Spinks, Peggy Valcke, John P A Ioannidis, et al.
Frontiers in Medicine|April 9, 2020
Patient Centricity in Patient Preference Studies: The Patient PerspectiveEline van Overbeeke, Inès Vanbinst, Aura Cecilia Jimenez-Moreno, et al.
Journal of Market Access & Health Policy|April 15, 2020
Economic evaluation of biosimilars for reimbursement purposes - what, when, how?Evelien Moorkens, Hannah Broux, Isabelle Huys, et al.
Targeted Oncology|November 19, 2013
Market access of cancer drugs in European countries: improving resource allocationKim Pauwels, Isabelle Huys, Minne Casteels, et al.
Expert Opinion on Biological Therapy|May 26, 2025
Evolving global regulatory landscape for approval of biosimilars: current challenges and opportunities for convergenceElif Car, Liese Barbier, Isabelle Huys, et al.
Health Research Policy and Systems|July 6, 2023
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysisYannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.
Plos One|March 29, 2017
Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory studyElfi De Weerdt, Thomas De Rijdt, Steven Simoens, et al.
Pageof 21